GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London Stock Exchange Other stock markets 11:35:13 2023-12-08 am EST			5-day change	1st Jan Change
1,434.4 ^GBX	+0.13%		-0.11%	-0.22%

Dec. 07	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT
Dec. 07	THG backer Kelso pushes for demerger to trim "inherent" valuation gap	AN

Gsk Announces Largest Private Financial Contribution To Cihr's Team Grants Initiative Addressing Threats To Canadian Lung Health

September 26, 2023 at 08:30 am EDT

Sept 26 (Reuters) - GSK plc:

* GSK ANNOUNCES LARGEST PRIVATE FINANCIAL CONTRIBUTION TO CIHR'S TEAM GRANTS INITIATIVE ADDRESSING THREATS TO CANADIAN LUNG HEALTH

* GSK - INVESTING $2 MILLION IN RESEARCH TO ADDRESS ONGOING, NEW, AND EMERGING THREATS TO LUNG HEALTH IN CANADA Source text for Eikon: Further company coverage:

Latest news about GSK plc

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Dec. 07	MT
THG backer Kelso pushes for demerger to trim "inherent" valuation gap	Dec. 07	AN
Frasers confident; DS Smith profit down, CEO to leave	Dec. 07	AN
GSK : Receives a Buy rating from Deutsche Bank	Dec. 06	ZD
Merck KGaA suffers major blow as MS drug fails in late-stage trials	Dec. 05	RE
Anything is possible	Dec. 05
JPMorgan Raises GSK PT, Maintains Underweight Rating	Dec. 05	MT
Analyst recommendations: Broadcom, Deere & Co, Rio Tinto, Lululemon, Nike...	Dec. 05
Goldman lifts Landsec and British Land	Dec. 05	AN
GSK : JP Morgan keeps a Sell rating	Dec. 05	ZD
GSK to Discontinue Manufacturing Integrilin Due to Ingredient Supply Issue	Dec. 01	MT
EMA: GLAXOSMITHKLINE IN AGREEMENT WITH EMA INFORMED GSK WILL DIS…	Dec. 01	RE
GSK : JP Morgan keeps a Sell rating	Dec. 01	ZD
GSK : Deutsche Bank reaffirms its Buy rating	Dec. 01	ZD
Hopes of an end to rate hikes lift UK shares, for now...	Dec. 01
UK Stocks-Factors to watch on Dec 1	Dec. 01	RE
GSK CEO Projects Over GBP1 Billion in RSV Vaccine Sales in First Year	Dec. 01	MT
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year	Nov. 30	RE
Transcript : GSK plc - Special Call	Nov. 30	CI
Pfizer disappointed in RSV shot's market share, CFO says	Nov. 28	RE
Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company	Nov. 28	MT
GSK : Receives a Buy rating from Deutsche Bank	Nov. 28	ZD
GSK Says Phase 3 Study of Blenrep With BorDex in Multiple Myeloma Meets Primary Endpoint	Nov. 27	MT
GSK announces positive results from Blenrep phase 3 blood cancer trial	Nov. 27	AN
GSK: encouraging results in multiple myeloma	Nov. 27	CF

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).

Sector

Pharmaceuticals

Calendar

2024-01-07 - JPMorgan Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : Q3 exceeded expectations; outlook upgraded ‘again’

November 01, 2023 at 11:02 am EDT

More Strategies

Ratings for GSK plc

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.34GBP

Average target price

17.27GBP

Spread / Average Target

+20.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	-0.22%	73 295 M $
ELI LILLY AND COMPANY	+63.47%	538 B $
NOVO NORDISK A/S	+42.56%	430 B $
JOHNSON & JOHNSON	-12.58%	372 B $
ABBVIE INC.	-7.63%	264 B $
MERCK & CO., INC.	-6.49%	263 B $
ROCHE HOLDING AG	-12.81%	232 B $
NOVARTIS AG	+1.35%	198 B $
ASTRAZENECA PLC	-9.77%	197 B $
PFIZER, INC.	-43.83%	163 B $